IGF-1 regulates cancer cell immune evasion in prostate cancer
Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1’s tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transc...
Uloženo v:
| Vydáno v: | Scientific reports Ročník 15; číslo 1; s. 38422 - 10 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
03.11.2025
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1’s tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa’s resistance to immunotherapy. |
|---|---|
| AbstractList | Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1’s tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa’s resistance to immunotherapy. Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1's tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa's resistance to immunotherapy.Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1's tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa's resistance to immunotherapy. Abstract Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other models. We investigated IGF-1’s tumor-intrinsic immune effects in PCa to understand mechanisms underlying its poor immunotherapy response. Transcriptional profiling of human (DU145, 22Rv1) and murine (Myc-CaP) PCa cells revealed that IGF-1 suppresses cytokine signalling, antigen processing and presentation, and additional immune regulatory pathways. We further examined the expression of components involved in cancer cell recognition and immune evasion: the antigen processing machinery and PD-L1 checkpoint. IGF-1 downregulated key elements such as transporters associated with antigen processing (TAPs), endoplasmic reticulum aminopeptidase-1 (ERAP-1), and Class I β2-microglobulin, without significantly altering Class I allele expression. These changes were associated with reduced surface presentation of Class I complexes on Myc-CaP cells, suggesting disrupted peptide transport, processing, and/or presentation. In contrast, IGF-1 upregulated the immune checkpoint CD274 (PD-L1) via IGF receptor/AKT/ERK-dependent signalling. Analysis of TCGA Firehose Legacy PCa data showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. Multiplex immunofluorescence in primary PCa confirmed increased PD-L1 in patients with high serum IGF-1, supporting its role in immune evasion. Overall, these findings reveal a novel IGF-1-driven immunosuppressive mechanism that may underlie PCa’s resistance to immunotherapy. |
| ArticleNumber | 38422 |
| Author | Doultsinos, Dimitrios Campo, Leticia Lang, Cameron R. James, Timothy Hamdy, Freddie C. Nandakumar, Ashwin M. Easton, Alistair Taylor, Avigail Mills, Ian G. Jainarayanan, Ashwin Verrill, Clare Mills, Jack V. Macaulay, Valentine M. Phyu, Su M. Kim, Jinseon Rieunier, Guillaume Barberis, Alessandro Parkes, Eileen E. |
| Author_xml | – sequence: 1 givenname: Ashwin M. surname: Nandakumar fullname: Nandakumar, Ashwin M. email: ashwin.nandakumar@nds.ox.ac.uk organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 2 givenname: Alessandro surname: Barberis fullname: Barberis, Alessandro organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 3 givenname: Jinseon surname: Kim fullname: Kim, Jinseon organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 4 givenname: Cameron R. surname: Lang fullname: Lang, Cameron R. organization: Department of Oncology, University of Oxford – sequence: 5 givenname: Jack V. surname: Mills fullname: Mills, Jack V. organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 6 givenname: Guillaume surname: Rieunier fullname: Rieunier, Guillaume organization: Department of Oncology, University of Oxford – sequence: 7 givenname: Dimitrios surname: Doultsinos fullname: Doultsinos, Dimitrios organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 8 givenname: Avigail surname: Taylor fullname: Taylor, Avigail organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 9 givenname: Ashwin surname: Jainarayanan fullname: Jainarayanan, Ashwin organization: Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, The University of Oxford – sequence: 10 givenname: Su M. surname: Phyu fullname: Phyu, Su M. organization: Department of Oncology, University of Oxford – sequence: 11 givenname: Leticia surname: Campo fullname: Campo, Leticia organization: Department of Oncology, University of Oxford – sequence: 12 givenname: Alistair surname: Easton fullname: Easton, Alistair organization: Department of Oncology, University of Oxford – sequence: 13 givenname: Eileen E. surname: Parkes fullname: Parkes, Eileen E. organization: Department of Oncology, University of Oxford – sequence: 14 givenname: Timothy surname: James fullname: James, Timothy organization: Department of Biochemistry, Oxford University Hospitals NHS Foundation Trust – sequence: 15 givenname: Freddie C. surname: Hamdy fullname: Hamdy, Freddie C. organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 16 givenname: Clare surname: Verrill fullname: Verrill, Clare organization: Nuffield Department of Surgical Sciences, University of Oxford, Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust – sequence: 17 givenname: Ian G. surname: Mills fullname: Mills, Ian G. organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 18 givenname: Valentine M. surname: Macaulay fullname: Macaulay, Valentine M. organization: Nuffield Department of Surgical Sciences, University of Oxford, Oxford Cancer Centre, Churchill Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41184420$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1LxDAQhoMofv8BD1Lw4qWaTJLd5OBBxI8FwYueQ5pOly5tqkkr-O9Nt-sHHswlmeGZdzLzHpBt33kk5ITRC0a5uoyCSa1yCjIHAKVyuUX2gYoUcoDtX-89chzjiqYjQQumd8meYEwJAXSfXC3u73KWBVwOje0xZs56hyFz2DRZ3baDxwzfbaw7n9U-ew1d7BO3wY7ITmWbiMeb-5C83N0-3zzkj0_3i5vrx9wJrvq8VHzGQLq51YVSvJxLLBRWQmOlCyYLOdOIpdYwn2kOrNJOUmcFgEBeUS34IVlMumVnV-Y11K0NH6aztVknurA0NvS1a9AUFjVyxdlYKCpl2bxE7mjKMO4qlbTOJ600y9uAsTdtHcdxrcduiIbDLO1GcCETevYHXXVD8GnSNQVaKjUKnm6ooWix_P7e15ITABPg0vZiwOobYdSMZprJTJPMNGszzdibT0UxwX6J4af3P1Wf6EqdaQ |
| Cites_doi | 10.3389/fimmu.2019.00603 10.1093/jnci/87.4.280 10.3389/fonc.2021.707473 10.1038/s41388-022-02376-w 10.1073/pnas.94.17.8970 10.1016/j.cyto.2016.06.018 10.1016/j.ajpath.2018.02.014 10.1158/1538-7445.Am2020-lb-391 10.1155/2023/8295113 10.1158/0008-5472.CAN-17-3498 10.1038/s43018-019-0007-9 10.1074/jbc.271.8.4280 10.1016/j.isci.2018.10.021 10.1161/ATVBAHA.107.156257 10.1038/s41467-022-30257-z 10.1126/scisignal.2004088 10.1002/ijc.33416 10.1016/j.apsb.2023.04.001 10.1200/JCO.2001.19.8.2189 10.1007/s00018-021-03828-4 10.1158/1078-0432.CCR-07-4879 10.1158/1078-0432.CCR-20-3805 10.1007/s10585-017-9848-8 10.1189/jlb.0404248 10.1158/0008-5472.CAN-05-3441 10.1371/journal.pone.0058428 10.3390/cancers13081776 10.1016/j.molimm.2018.03.026 10.1677/joe.1.06486 10.1111/j.1464-410X.2010.09556.x 10.1016/S0002-9440(10)63151-3 10.1186/1472-6750-13-104 10.15252/emmm.201303376 10.3389/fimmu.2022.844866 10.1038/s41419-022-05292-9 10.1126/science.aad0095 10.2337/dc08-0553 10.1158/0008-5472.CAN-15-1551 10.3390/cancers14235747 10.1126/science.8418502 10.1016/0168-9525(93)90205-v |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA |
| DOI | 10.1038/s41598-025-22288-5 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Science Database Biological Science Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_bae9e3831f0944f8a17de3c083113cf8 41184420 10_1038_s41598_025_22288_5 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Cancer Research UK funderid: https://doi.org/10.13039/501100000289 – fundername: UCARE – fundername: University of Oxford funderid: https://doi.org/10.13039/501100000769 – fundername: Prostate Cancer UK funderid: https://doi.org/10.13039/501100000771 – fundername: John Black Charitable Foundation funderid: https://doi.org/10.13039/501100020400 |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFFHD AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 88A 8FK K9. M48 PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c438t-d836125c7a9b883d75eb8ef49ef9b15b569eed992769321f9c50ca4224e3f0943 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001608129300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Mon Nov 10 19:21:42 EST 2025 Tue Nov 04 16:34:43 EST 2025 Tue Nov 04 14:42:23 EST 2025 Fri Nov 07 01:56:51 EST 2025 Wed Nov 05 20:45:22 EST 2025 Tue Nov 04 01:11:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2025. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c438t-d836125c7a9b883d75eb8ef49ef9b15b569eed992769321f9c50ca4224e3f0943 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3268295888?pq-origsite=%requestingapplication% |
| PMID | 41184420 |
| PQID | 3268295888 |
| PQPubID | 2041939 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bae9e3831f0944f8a17de3c083113cf8 proquest_miscellaneous_3268444345 proquest_journals_3268295888 pubmed_primary_41184420 crossref_primary_10_1038_s41598_025_22288_5 springer_journals_10_1038_s41598_025_22288_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-11-03 |
| PublicationDateYYYYMMDD | 2025-11-03 |
| PublicationDate_xml | – month: 11 year: 2025 text: 2025-11-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | MC Haffner (22288_CR36) 2018; 188 R Kooijman (22288_CR6) 2004; 76 A Mpakali (22288_CR11) 2019; 113 Q Xie (22288_CR40) 2023; 13 Y Pan (22288_CR33) 2013; 8 E Succurro (22288_CR38) 2008; 31 T Aleksic (22288_CR32) 2018; 78 22288_CR30 C Duan (22288_CR31) 1996; 271 X Qiu (22288_CR23) 2022; 13 T Ito (22288_CR35) 2004; 164 DW Andrews (22288_CR16) 2021; 27 M Resnicoff (22288_CR14) 1994; 54 22288_CR26 D Bilbao (22288_CR7) 2014; 6 J Trowsdale (22288_CR10) 1993; 9 A Nordstrand (22288_CR17) 2017; 34 MG Sanda (22288_CR24) 1995; 87 GO Hellawell (22288_CR2) 2002; 62 J Trojan (22288_CR13) 1993; 259 DW Andrews (22288_CR15) 2001; 19 M Groettrup (22288_CR25) 1997; 94 MM Chitnis (22288_CR1) 2008; 14 D Ajona (22288_CR19) 2020; 1 BW Turney (22288_CR3) 2011; 107 S Zhang (22288_CR29) 2022; 13 RC Travis (22288_CR4) 2016; 76 PA Watson (22288_CR22) 2005; 65 A Takahashi (22288_CR28) 2021; 11 BC Taylor (22288_CR12) 2022; 13 EL Watts (22288_CR5) 2021; 148 22288_CR21 S Lamble (22288_CR42) 2013; 13 EM Van Allen (22288_CR43) 2015; 350 22288_CR20 ILAA Marti (22288_CR27) 2021; 78 C Giuliani (22288_CR34) 2006; 189 22288_CR41 E Alfaro-Arnedo (22288_CR39) 2022; 41 22288_CR18 RL Lopes (22288_CR8) 2016; 85 N Vitkin (22288_CR9) 2019; 10 S Sukhanov (22288_CR37) 2007; 27 |
| References_xml | – volume: 10 start-page: 603 year: 2019 ident: 22288_CR9 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00603 – volume: 87 start-page: 280 year: 1995 ident: 22288_CR24 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/87.4.280 – volume: 11 start-page: 707473 year: 2021 ident: 22288_CR28 publication-title: Front. Oncol. doi: 10.3389/fonc.2021.707473 – volume: 41 start-page: 3625 year: 2022 ident: 22288_CR39 publication-title: Oncogene doi: 10.1038/s41388-022-02376-w – volume: 94 start-page: 8970 year: 1997 ident: 22288_CR25 publication-title: Proc. Natl. Acad. Sci. U S A doi: 10.1073/pnas.94.17.8970 – volume: 85 start-page: 123 year: 2016 ident: 22288_CR8 publication-title: Cytokine doi: 10.1016/j.cyto.2016.06.018 – volume: 188 start-page: 1478 year: 2018 ident: 22288_CR36 publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2018.02.014 – ident: 22288_CR21 doi: 10.1158/1538-7445.Am2020-lb-391 – ident: 22288_CR26 doi: 10.1155/2023/8295113 – volume: 78 start-page: 3497 year: 2018 ident: 22288_CR32 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-3498 – volume: 1 start-page: 75 year: 2020 ident: 22288_CR19 publication-title: Nat. Cancer doi: 10.1038/s43018-019-0007-9 – volume: 271 start-page: 4280 year: 1996 ident: 22288_CR31 publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.8.4280 – volume: 62 start-page: 2942 year: 2002 ident: 22288_CR2 publication-title: Cancer Res. – ident: 22288_CR18 doi: 10.1016/j.isci.2018.10.021 – volume: 27 start-page: 2684 year: 2007 ident: 22288_CR37 publication-title: Arterioscler. Thromb. Vasc Biol. doi: 10.1161/ATVBAHA.107.156257 – volume: 13 start-page: 2559 year: 2022 ident: 22288_CR23 publication-title: Nat. Commun. doi: 10.1038/s41467-022-30257-z – ident: 22288_CR30 doi: 10.1126/scisignal.2004088 – volume: 148 start-page: 2274 year: 2021 ident: 22288_CR5 publication-title: Int. J. Cancer doi: 10.1002/ijc.33416 – volume: 13 start-page: 2963 year: 2023 ident: 22288_CR40 publication-title: Acta Pharm. Sin B doi: 10.1016/j.apsb.2023.04.001 – volume: 19 start-page: 2189 year: 2001 ident: 22288_CR15 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2001.19.8.2189 – volume: 78 start-page: 5303 year: 2021 ident: 22288_CR27 publication-title: Cell. Mol. Life Sci. doi: 10.1007/s00018-021-03828-4 – volume: 14 start-page: 6364 year: 2008 ident: 22288_CR1 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4879 – volume: 27 start-page: 1912 year: 2021 ident: 22288_CR16 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-3805 – volume: 34 start-page: 261 year: 2017 ident: 22288_CR17 publication-title: Clin. Exp. Metastasis doi: 10.1007/s10585-017-9848-8 – volume: 76 start-page: 862 year: 2004 ident: 22288_CR6 publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.0404248 – volume: 65 start-page: 11565 year: 2005 ident: 22288_CR22 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-3441 – volume: 8 start-page: e58428 year: 2013 ident: 22288_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0058428 – ident: 22288_CR41 doi: 10.3390/cancers13081776 – volume: 113 start-page: 50 year: 2019 ident: 22288_CR11 publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2018.03.026 – volume: 189 start-page: 605 year: 2006 ident: 22288_CR34 publication-title: J. Endocrinol. doi: 10.1677/joe.1.06486 – volume: 107 start-page: 1488 year: 2011 ident: 22288_CR3 publication-title: BJU Int. doi: 10.1111/j.1464-410X.2010.09556.x – volume: 164 start-page: 623 year: 2004 ident: 22288_CR35 publication-title: Am. J. Pathol. doi: 10.1016/S0002-9440(10)63151-3 – volume: 13 start-page: 104 year: 2013 ident: 22288_CR42 publication-title: BMC Biotechnol. doi: 10.1186/1472-6750-13-104 – volume: 6 start-page: 1423 year: 2014 ident: 22288_CR7 publication-title: EMBO Mol. Med. doi: 10.15252/emmm.201303376 – volume: 13 start-page: 844866 year: 2022 ident: 22288_CR12 publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.844866 – volume: 54 start-page: 2218 year: 1994 ident: 22288_CR14 publication-title: Cancer Res. – volume: 13 start-page: 844 year: 2022 ident: 22288_CR29 publication-title: Cell. Death Dis. doi: 10.1038/s41419-022-05292-9 – volume: 350 start-page: 207 year: 2015 ident: 22288_CR43 publication-title: Science doi: 10.1126/science.aad0095 – volume: 31 start-page: 1886 year: 2008 ident: 22288_CR38 publication-title: Diabetes Care doi: 10.2337/dc08-0553 – volume: 76 start-page: 2288 year: 2016 ident: 22288_CR4 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1551 – ident: 22288_CR20 doi: 10.3390/cancers14235747 – volume: 259 start-page: 94 year: 1993 ident: 22288_CR13 publication-title: Sci. (New York N Y) doi: 10.1126/science.8418502 – volume: 9 start-page: 117 year: 1993 ident: 22288_CR10 publication-title: Trends Genet. doi: 10.1016/0168-9525(93)90205-v |
| SSID | ssj0000529419 |
| Score | 2.4632201 |
| Snippet | Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in other... Abstract Insulin-like growth factor-1 (IGF-1) is associated with prostate cancer (PCa) development and lethality and exhibits immunosuppressive properties in... |
| SourceID | doaj proquest pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 38422 |
| SubjectTerms | 631/67 631/67/580 AKT protein Aminopeptidase Androgens Animals Antigen Presentation Antigen processing Autophagy B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Cell cycle Cell Line, Tumor Cell recognition Cytokines Down-regulation Endoplasmic reticulum Gene Expression Regulation, Neoplastic Genes Humanities and Social Sciences Humans Immune checkpoint Immune Evasion Immune response Immunofluorescence Immunotherapy Insulin-like growth factor I Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - immunology Insulin-Like Growth Factor I - metabolism Insulin-like growth factor-binding protein 5 Insulin-like growth factors Lethality Lupus Male Metastasis Mice multidisciplinary Myc protein PD-L1 protein Peptides Prostate cancer Prostatic Neoplasms - genetics Prostatic Neoplasms - immunology Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Proteins Science Science (multidisciplinary) Signal processing Signal Transduction Tumor Escape β2 Microglobulin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEB9KUehF_Kh1tZUI3jR089VNDh5a8alQigcLvYUkOwvvsi3vvRb63ztJ9j0rtnjxujssye83YT6yMwPwvgukRjgILnTvuE7C8YBIMQ9qE1HIpFUpFD7tzs7sxYX7cWfUV_4nrLYHrsAdxoAOKYwSAwUierBBdD2qlAdkCZWGUuZLXs-dYKp29ZZOCzdVybTKHi7JUuVqMml4TnpYbv6wRKVh_31e5l83pMXwzJ7Ck8ljZMd1pc9gC8fn8LjOkLx9AZ--f51xwRZ1pjwuWco8LljOyLN5rv5AhjchJ8XYfGRXucqD5CaxXTifffn5-RufZiJwQs2ueG9V9klSF1y0VvWdwWhx0A4HF4WJ5siR1XNO5hmHUgwumTYFTYYaVUZQvYTt8XLEV8AsRcVGRjqDqtV9iDF1pfWL0fGoN21s4MMaH39VW1_4cmWtrK9oekLTFzS9aeAkQ7iRzG2rywMi009k-n-R2cD-mgA_naWlJwfTSmcoVG_g3eY1nYIMZBjx8rrKaK2VpnXsVeI2K9EUQ2kt2wY-rpn8_fGHN_T6f2zoDezIrHI5D632YXu1uMYDeJRuVvPl4m3R2V_3uupM priority: 102 providerName: Directory of Open Access Journals |
| Title | IGF-1 regulates cancer cell immune evasion in prostate cancer |
| URI | https://link.springer.com/article/10.1038/s41598-025-22288-5 https://www.ncbi.nlm.nih.gov/pubmed/41184420 https://www.proquest.com/docview/3268295888 https://www.proquest.com/docview/3268444345 https://doaj.org/article/bae9e3831f0944f8a17de3c083113cf8 |
| Volume | 15 |
| WOSCitedRecordID | wos001608129300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LjtQwzGJ3QeLC-zGwjIrEDaJtmmSbHBBi0Q6sxI4qBNJwqprURXPpDO3sSvw9dtqZFeJx4dJDY1VubMev2AZ4kVfERthIIXXthA7SiQqRfB7UxqPMglaxUPhjPp_bxcIVY8CtH69Vbs_EeFDXq8Ax8iMyM2zmDDlsb9bfBU-N4uzqOEJjDw64S4KKV_eKXYyFs1haurFWJlX2qCd9xTVlmREc-rDC_KKPYtv-P9mav-VJo_qZ3f5fxO_ArdHwTN4OnHIXrmF7D24Moyh_3IfXZ-9nQibdMJoe-yQwO3QJB_aTJReRYIKXFcfWkmWbrLlYhOBGsAfwZXb6-d0HMY5WELT5diNqq9i0CXnlvLWqzg16i4122DgvjTfHjpSncxmPSsxk44JJQ6VJ36Nq-DLiQ9hvVy0-hsSSc20yT6KsUl1X3oc8dpAx2h_XJvUTeLnd4HI9dNAoY-Zb2XIgR0nkKCM5SjOBE6bBDpK7X8cXq-5bOQoTKXh0SK61ZFR0YyuZ16gCD02TKjR2AodbUpSjSPblFR0m8Hy3TMLEG1m1uLoYYLTWShMejwbK7zDR5IppnaUTeLVlhauP__2Hnvwbl6dwM2Nu5EC1OoT9TXeBz-B6uNws-24Ke_kij087hYOT03nxaRqjBvQ8z4ppZHdaKc7Oi68_AWHJ_34 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL70egQJDgBFbjV2MfKsRr6arLqoci9RZiZ1LtJbtstkX9U_xGPE6yFeJx64FrYjkTz3ieHn8AL_IyiBHWnHFVWaY8t6xEDDEPKu2QC69kbBSe5NOpOTqyBxvwY-iFoWOVg06Mirqae8qRbwc3wwirQ8D2ZvGNEWoUVVcHCI1OLPbx7HsI2drd8YfA35dCjD4evt9jPaoAC981K1YZSVbd56V1xsgq1-gM1spibR3XTu_YYDesFYQSKHhtvc58qYKpQ1nTObww7yW4HNwIYeJRwYN1ToeqZorbvjcnk2a7DfaRetiEZpRqMUz_Yv8iTMCffNvf6rLR3I1u_m8LdQtu9I51-rbbCbdhA5s7cLWD2jy7C7vjTyPG0yUeE14ZtqkncV-mVLhIZ9QkgymelpQ7TGdNuqBmmDCuH3YPvlwI7fdhs5k3-BBSkwe1JlxQVTJTVemcz-MNOVq5nUpnLoFXA0OLRXdDSBEr-9IUHfuLwP4isr_QCbwjnq9H0u3e8cF8eVz0yiI4MGhRGsmJFFWbkucVSk-gcFz62iSwNbC-6FVOW5zzPYHn69dBWdBClg3OT7oxSimpAh0POklbU6JCqKmUyBJ4PYje-eR__6FH_6blGVzbO_w8KSbj6f5juC5oJ1BSXm7B5mp5gk_gij9dzdrl07iVUvh60SL5E80uVJQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8hAX3tBAASPBCaLGr8Y-VAgoC6tWqz2A1JtJnEm1l-x2sy3qX-PX4XGSrRCPWw9cE8uaxN88POPxB_AyLwKMsOYpV5VNlec2LRDDngeVLpELr2RsFD7MJxNzdGSnG_Bj6IWhY5WDTYyGupp7ypHvhDDDCKtpw1b3xyKm-6O3i5OUGKSo0jrQaXQQOcDz72H71u6N98NavxJi9PHLh89pzzCQBhnMKq2MJA_v88KWxsgq11garJXF2pZcl3rXBh9irSDGQMFr63XmCxXcHsqazuSFea_A1ZwuLY_HBqfr_A5V0BS3fZ9OJs1OG3wl9bMJnVLaxaT6F18YKQP-FOf-VqONrm90-3_-aXfgVh9ws3edhtyFDWzuwfWOgvP8PuyNP41SzpZ4TDxm2DJParBkVNBgM2qeQYZnBeUU2axhC2qSCeP6YQ_g66XI_hA2m3mDW8BMHsydKIMJk5mqirL0ebw5R6tyt9JZmcDrYXHdors5xMWKvzSug4ILUHARCk4n8J7Wfz2Sbv2OD-bLY9cbkRDYoEVpJCdRVG0KnlcoPZHFcelrk8D2AAPXm6LWXWAggRfr18GI0I8sGpyfdmOUUlIFOR51qFtLosIWVCmRJfBmgOHF5H__oMf_luU53AhIdIfjycETuClIKShXL7dhc7U8xadwzZ-tZu3yWdQqBt8uG5E_AZ9MXVE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IGF-1+regulates+cancer+cell+immune+evasion+in+prostate+cancer&rft.jtitle=Scientific+reports&rft.au=Nandakumar%2C+Ashwin+M&rft.au=Barberis%2C+Alessandro&rft.au=Kim%2C+Jinseon&rft.au=Lang%2C+Cameron+R&rft.date=2025-11-03&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-025-22288-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |